These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 2876441)

  • 21. Sedation and sleep induced by high doses of apomorphine after blockade of D-1 receptors by SCH 23390.
    Gessa GL; Porceddu ML; Collu M; Mereu G; Serra M; Ongini E; Biggio G
    Eur J Pharmacol; 1985 Feb; 109(2):269-74. PubMed ID: 2859998
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuroleptic-induced reduction of quipazine-elicited head-twitches in rats: possible involvement of striatal dopaminergic supersensitivity.
    Dall'Olio R; Vaccheri A; Gandolfi O; Roncada P; Montanaro N
    Pharmacol Biochem Behav; 1988 Dec; 31(4):941-4. PubMed ID: 2908069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Presynaptic dopamine receptors in the pithed rat: characterization with apomorphine and comparison with central dopamine autoreceptors.
    Hietala J; MacDonald E; Scheinin M
    Acta Pharmacol Toxicol (Copenh); 1986 Oct; 59(4):291-7. PubMed ID: 3799208
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of morphine on rat behaviour in the elevated plus maze: the role of central amygdala dopamine receptors.
    Rezayof A; Hosseini SS; Zarrindast MR
    Behav Brain Res; 2009 Sep; 202(2):171-8. PubMed ID: 19463698
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential effects of the dopamine antagonist remoxipride on apomorphine induced behaviour in the rat.
    Ståhle L; Ljungberg T; Rodebjer A; Ogren SO; Ungerstedt U
    Pharmacol Toxicol; 1987 Mar; 60(3):227-32. PubMed ID: 2884654
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased grooming behaviour is induced by apomorphine in mice treated with discriminant benzamide derivatives.
    Vasse M; Protais P
    Eur J Pharmacol; 1988 Oct; 156(1):1-11. PubMed ID: 2905270
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Apomorphine anorexia: the role of dopamine receptors in the ventral forebrain.
    Towell A; Willner P; Muscat R
    Psychopharmacology (Berl); 1988; 96(1):135-41. PubMed ID: 2906442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence that apomorphine and pergolide induce rotation in rats by different actions on D1 and D2 receptor sites.
    Herrera-Marschitz M; Ungerstedt U
    Eur J Pharmacol; 1984 Feb; 98(2):165-76. PubMed ID: 6143675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dopamine autoreceptor and postsynaptic receptor blocking potency of neuroleptics.
    Kendler KS; Bracha HS; Davis KL
    Eur J Pharmacol; 1982 Apr; 79(3-4):217-23. PubMed ID: 6124428
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rapid tolerance to neuroleptic-induced stimulation of dopamine release in freely moving rats.
    Di Chiara G; Imperato A
    J Pharmacol Exp Ther; 1985 Nov; 235(2):487-94. PubMed ID: 2865354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of the dopamine D-1 antagonist SCH 23390 on rotational behaviour induced by apomorphine and pergolide in 6-hydroxy-dopamine denervated rats.
    Herrera-Marschitz M; Ungerstedt U
    Eur J Pharmacol; 1985 Mar; 109(3):349-54. PubMed ID: 3157586
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased investigative activity after presynaptic dopaminergic stimulation measured by a fixed-interval recording procedure.
    Höglund AU; Meyerson BJ
    Pharmacol Biochem Behav; 1985 Mar; 22(3):403-6. PubMed ID: 2859606
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SCH 23390 may alter dopamine-mediated motor behaviour via striatal D-1 receptors.
    Boyce S; Kelly E; Davis A; Fleminger S; Jenner P; Marsden CD
    Biochem Pharmacol; 1985 May; 34(10):1665-9. PubMed ID: 2988552
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Repeated administration of sulpiride for three weeks produces behavioural and biochemical evidence for cerebral dopamine receptor supersensitivity.
    Jenner P; Hall MD; Murugaiah K; Rupniak N; Theodorou A; Marsden CD
    Biochem Pharmacol; 1982 Feb; 31(3):325-8. PubMed ID: 7200363
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interaction of SCH 23390, a D-1-selective antagonist, with the anterior pituitary D-2 receptors and prolactin secretion in the rat.
    Apud JA; Masotto C; Ongini E; Racagni G
    Eur J Pharmacol; 1985 Jun; 112(2):187-93. PubMed ID: 2863153
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Some behavioural effects of chloroquine in rats suggesting dopaminergic activation.
    Amabeoku GJ
    Indian J Med Res; 1994 Feb; 99():87-94. PubMed ID: 8005645
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of dopamine D-1 and D-2 antagonists on decision making by rats: no reversal of neuroleptic-induced attenuation by scopolamine.
    Ljungberg T; Enquist M
    J Neural Transm Gen Sect; 1990; 82(3):167-79. PubMed ID: 1979001
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dopamine agonist-induced locomotor activity in rats treated with 6-hydroxydopamine at differing ages: functional supersensitivity of D-1 dopamine receptors in neonatally lesioned rats.
    Breese GR; Napier TC; Mueller RA
    J Pharmacol Exp Ther; 1985 Aug; 234(2):447-55. PubMed ID: 3926987
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of SCH 39166, a novel dopamine D1 receptor antagonist, on [3H]acetylcholine release in rat striatal slices.
    Tedford CE; Crosby G; Iorio LC; Chipkin RE
    Eur J Pharmacol; 1992 Feb; 211(2):169-76. PubMed ID: 1535318
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Yawning and suppression of exploration in amphetamine-treated rats, incompatibility with the autoreceptor hypothesis.
    Ståhle L; Ungerstedt U
    Psychopharmacology (Berl); 1989; 97(4):553-60. PubMed ID: 2567032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.